Immune cell therapy shows promise for tough lymphoma cases
NCT ID NCT03029338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a personalized cell therapy called CD19 CAR T cells in 20 adults with relapsed or refractory B-cell lymphoma. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells, and infusing them back. The main goals were to check safety and see if the cells could shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19 CAR T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat B-cell lymphoma.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so results may not apply to everyone. Side effects from CAR T therapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China